Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature
Abstract Monotherapy with anti-programmed cell death protein 1 (PD-1) monoclonal antibody has been approved for the treatment of advanced non-small cell lung cancer with positive programmed cell death-ligand 1 (PD-L1) expression and oncogene wild type, which revealed survival benefit compared with c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-01749-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544519996145664 |
|---|---|
| author | Guangjian Yang Linyan Tian Yan Wang |
| author_facet | Guangjian Yang Linyan Tian Yan Wang |
| author_sort | Guangjian Yang |
| collection | DOAJ |
| description | Abstract Monotherapy with anti-programmed cell death protein 1 (PD-1) monoclonal antibody has been approved for the treatment of advanced non-small cell lung cancer with positive programmed cell death-ligand 1 (PD-L1) expression and oncogene wild type, which revealed survival benefit compared with chemotherapy. Nevertheless, certain patients develop rapid progression on anti-PD-1 inhibitor monotherapy. This novel pattern is called hyperprogressive disease (HPD), and the underlying mechanism and molecular characteristics still leaves not clear. Here, we reported two heavily pretreated advanced lung adenocarcinoma cases with HER2 exon 20 insertion who presented HPD after two cycles of anti-PD-1 inhibitor sintilimab monotherapy, and they both carried co-alterations in the PI3K/AKT/mTOR and cell cycle signaling pathway. We speculated that HER2 exon 20 insertion might be viewed as a potential biomarker to avoid single-agent immunotherapy in certain patients with driver mutations, or timely guide proper treatment strategies. |
| format | Article |
| id | doaj-art-7924640bed58443aa6325e37049091fb |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-7924640bed58443aa6325e37049091fb2025-01-12T12:29:12ZengSpringerDiscover Oncology2730-60112025-01-0116111010.1007/s12672-025-01749-3Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literatureGuangjian Yang0Linyan Tian1Yan Wang2Department of Respiratory Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical SciencesDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Monotherapy with anti-programmed cell death protein 1 (PD-1) monoclonal antibody has been approved for the treatment of advanced non-small cell lung cancer with positive programmed cell death-ligand 1 (PD-L1) expression and oncogene wild type, which revealed survival benefit compared with chemotherapy. Nevertheless, certain patients develop rapid progression on anti-PD-1 inhibitor monotherapy. This novel pattern is called hyperprogressive disease (HPD), and the underlying mechanism and molecular characteristics still leaves not clear. Here, we reported two heavily pretreated advanced lung adenocarcinoma cases with HER2 exon 20 insertion who presented HPD after two cycles of anti-PD-1 inhibitor sintilimab monotherapy, and they both carried co-alterations in the PI3K/AKT/mTOR and cell cycle signaling pathway. We speculated that HER2 exon 20 insertion might be viewed as a potential biomarker to avoid single-agent immunotherapy in certain patients with driver mutations, or timely guide proper treatment strategies.https://doi.org/10.1007/s12672-025-01749-3Hyperprogressive diseasePD-1 inhibitorHER2Exon 20 insertionNon-small cell lung cancerCase report |
| spellingShingle | Guangjian Yang Linyan Tian Yan Wang Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature Discover Oncology Hyperprogressive disease PD-1 inhibitor HER2 Exon 20 insertion Non-small cell lung cancer Case report |
| title | Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature |
| title_full | Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature |
| title_fullStr | Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature |
| title_full_unstemmed | Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature |
| title_short | Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature |
| title_sort | hyperprogressive disease induced by pd 1 inhibitor monotherapy in lung adenocarcinoma with her2 exon 20 insertion report of two cases and review of literature |
| topic | Hyperprogressive disease PD-1 inhibitor HER2 Exon 20 insertion Non-small cell lung cancer Case report |
| url | https://doi.org/10.1007/s12672-025-01749-3 |
| work_keys_str_mv | AT guangjianyang hyperprogressivediseaseinducedbypd1inhibitormonotherapyinlungadenocarcinomawithher2exon20insertionreportoftwocasesandreviewofliterature AT linyantian hyperprogressivediseaseinducedbypd1inhibitormonotherapyinlungadenocarcinomawithher2exon20insertionreportoftwocasesandreviewofliterature AT yanwang hyperprogressivediseaseinducedbypd1inhibitormonotherapyinlungadenocarcinomawithher2exon20insertionreportoftwocasesandreviewofliterature |